Figure 3.

Signatures of Dopaminergic Medication in the Metabolome

(A) Overview of results regarding dopaminergic medication, summarizing results significant after correcting for multiple testing (FDR < 0.05). Note that the global tests have no effect sign.

(B) Change of 3-O-methyldopamine and cystathionine in dependency on change in levodopa dosage. In the lower panel, connected dots belong to the same individual. The lower panel shows that the change in cystathionine was not dependent on levodopa dosage, while for 3-O-methyldopamine, high levels led to less change.

(C) Association of bile acids and histidine with UPDRS III scores (all FDR < 0.05). BL, baseline; FU1, follow-up I; FU2, follow-up II; PC, phosphatidylcholine; TG, triglyceride; UPDRS, Unified Parkinson’s Disease Rating Scale.